We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$750M
AUM Growth
+$262M
Cap. Flow
+$205M
Cap. Flow %
27.3%
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
40
Closed
5

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$14.3M
2
ALGN icon
Align Technology
ALGN
+$13.8M
3
WBA
Walgreens Boots Alliance
WBA
+$13.5M
4
AMGN icon
Amgen
AMGN
+$12M
5
CNC icon
Centene
CNC
+$9.49M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.67M
2
SYK icon
Stryker
SYK
+$4.15M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.91M
4
BDX icon
Becton Dickinson
BDX
+$1.79M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 92.09%
2 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$31.3M 4.17%
251,380
+51,730
+26% +$6.19M
AMGN icon
2
Amgen
AMGN
$198B
$25.5M 3.4%
155,450
+71,950
+86% +$12M
INCY icon
3
Incyte
INCY
$23.4B
$25M 3.33%
186,950
+36,550
+24% +$4.65M
CNC icon
4
Centene
CNC
$32.8B
$20.9M 2.79%
586,680
+283,420
+93% +$9.49M
UNH icon
5
UnitedHealth
UNH
$387B
$20.3M 2.71%
123,940
+13,940
+13% +$2.28M
GILD icon
6
Gilead Sciences
GILD
$167B
$19.7M 2.63%
290,428
+110,928
+62% +$7.8M
MDT icon
7
Medtronic
MDT
$106B
$19.5M 2.6%
242,500
-17,000
-7% -$1.33M
ELV icon
8
Elevance Health
ELV
$80.9B
$18.3M 2.43%
110,460
+89,860
+436% +$14.3M
ABT icon
9
Abbott
ABT
$175B
$18M 2.4%
405,500
– –
ILMN icon
10
Illumina
ILMN
$28.2B
$16.9M 2.25%
101,714
+46,408
+84% +$7.31M
ISRG icon
11
Intuitive Surgical
ISRG
$122B
$16.8M 2.24%
197,325
+116,325
+144% +$9.19M
SYK icon
12
Stryker
SYK
$123B
$16.1M 2.15%
122,570
-32,830
-21% -$4.15M
ALGN icon
13
Align Technology
ALGN
$12.7B
$15.6M 2.08%
+136,200
New +$13.8M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$15.5B
$15.5M 2.06%
106,600
+22,800
+27% +$2.97M
BIIB icon
15
Biogen
BIIB
$30.4B
$14.6M 1.95%
53,500
+4,500
+9% +$1.27M
HOLX
16
DELISTED
Hologic
HOLX
$14.6M 1.94%
342,490
+122,890
+56% +$5.01M
BSX icon
17
Boston Scientific
BSX
$65.4B
$14.2M 1.9%
572,000
+22,000
+4% +$535K
WBA
18
DELISTED
Walgreens Boots Alliance
WBA
$13.3M 1.78%
+160,409
New +$13.5M
LGND icon
19
Ligand Pharmaceuticals
LGND
$6.08B
$12.5M 1.67%
190,020
-9,602
-5% -$632K
BCR
20
DELISTED
CR Bard Inc.
BCR
$12M 1.6%
48,430
-2,670
-5% -$644K
AKRX
21
DELISTED
Akorn Inc
AKRX
$11.9M 1.59%
494,600
+34,600
+8% +$753K
EW icon
22
Edwards Lifesciences
EW
$49.4B
$11.8M 1.57%
375,000
– –
TEVA icon
23
Teva Pharmaceuticals
TEVA
$37.3B
$11.8M 1.57%
366,172
+131,182
+56% +$4.48M
SHPG
24
DELISTED
Shire pic
SHPG
$11.4M 1.53%
65,700
+41,700
+174% +$7.28M
REGN icon
25
Regeneron Pharmaceuticals
REGN
$70.9B
$11.4M 1.51%
29,300
-3,000
-9% -$1.11M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2017 Portfolio in Review

As of Q1 2017, Bellevue Group held 137 positions worth $750M, up 54% from $488M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $205M of net new capital in Q1 2017, opening 15 new positions and adding to 36 existing holdings. Its largest new stake was Align Technology: 136,200 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Stryker, an estimated $4.15M trimmed.

  • Bellevue Group's largest Q1 2017 buy was Align Technology: 136,200 shares worth $15.6M.
  • Bellevue Group added most to Elevance Health in Q1 2017, an estimated $14.3M increase.
  • Bellevue Group's biggest Q1 2017 reduction was Stryker, cutting an estimated $4.15M.
  • Bellevue Group fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $4.67M.
  • Bellevue Group's ten largest holdings make up 29% of its $750M portfolio in Q1 2017.
  • Bellevue Group opened 15 new positions and closed 5 in Q1 2017.
  • Bellevue Group's portfolio value rose 54% quarter-over-quarter to $750M.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.